HYPORT HN-A randomized, non inferiority trial to compare the the average global quality of life score following HYPofractionated radiotherapy versus conventional fractionation in Head and Neck cancer - HYPORT H

TATA MEDICAL CENTER KOLKATA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1)Age = 18 years
•2)ECOG performance status 0 - 2.
•3)Patients diagnosed with invasive squamous cell cancer of the head and neck region including lip, oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx
•4)Patients with non metastatic cancer, optimally staged with the following:
•a)Contrast enhanced CT or MRI scan of the neck and CT of the thorax (or whole body FDG PET-CT scan) for cancer lip, oral cavity, oropharynx, hypopharynx, supraglottis, glottis and subglottis
•b)Magnetic Resonance Imaging of the neck and Whole body PET-CT for cancer of nasopharynx
•5)Patients who are being treated with curative intent treatment either with radiotherapy or concurrent chemoradiotherapy, neoadjuvant chemotherapy followed by curative radiotherapy or chemoradiotherapy, or primary surgery followed by adjuvant radiotherapy or chemoradiotherapy. Patients must have a histopathological proof of malignancy, such as biopsy or postoperative histopathology report. Biopsies or surgeries done outside must have been reviewed for pathological confirmation and specimen adequacy at the treating institute.

•1)Concurrent illness like severe cardiac, renal or hepatic dysfunction and severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety after discussion in MDT
•2)Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.

发起方

TATA MEDICAL CENTER KOLKATA